TapewireFind a company

person · Reporting owner

Pruzanski Mark

Disclosed activity across 2 companies

Tapewire entity
43110
SEC CIK
0001559569

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Equillium, Inc.EQ · Entity 6560DirectorMay 28, 2026May 29, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Equillium, Inc.

Report date May 28, 2026 · Filed May 29, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.84 · Expires 2036-05-27Direct70,000 Reported balance After 2026-05-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-05-28 · Grant · Acquired 70,000 · Balance 70,000

F1: The option vests in twelve equal monthly installments commencing on the grant date of May 28, 2026, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in twelve equal monthly installments commencing on the grant date of May 28, 2026, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

INTERCEPT PHARMACEUTICALS, INC.

Report date November 08, 2023 · Filed November 13, 2023

Section 16 reporting ended · disclosed 2023-11-13. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2023-11-08 transaction · row 1
1 source row

Row 1 · 2023-11-08 · Other · Disposed 618,894 · Balance 0

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $266.01Direct0 Reported balance After 2023-11-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2023-11-08 · Disposition to issuer · Disposed 332 · Balance 0

F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $266.01Direct0 Reported balance After 2023-11-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2023-11-08 · Disposition to issuer · Disposed 5,401 · Balance 0

F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $161.16Direct0 Reported balance After 2023-11-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2023-11-08 · Disposition to issuer · Disposed 1,044 · Balance 0

F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $161.16Direct0 Reported balance After 2023-11-08 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2023-11-08 · Disposition to issuer · Disposed 31,506 · Balance 0

F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $94.29Direct0 Reported balance After 2023-11-08 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2023-11-08 · Disposition to issuer · Disposed 635 · Balance 0

F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $94.29Direct0 Reported balance After 2023-11-08 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2023-11-08 · Disposition to issuer · Disposed 29,865 · Balance 0

F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $107.18Direct0 Reported balance After 2023-11-08 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2023-11-08 · Disposition to issuer · Disposed 1,207 · Balance 0

F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $107.18Direct0 Reported balance After 2023-11-08 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2023-11-08 · Disposition to issuer · Disposed 38,793 · Balance 0

F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $58.74Direct0 Reported balance After 2023-11-08 transaction · row 10 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 10 · 2023-11-08 · Disposition to issuer · Disposed 207 · Balance 0

F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $58.74Direct0 Reported balance After 2023-11-08 transaction · row 11 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 11 · 2023-11-08 · Disposition to issuer · Disposed 45,293 · Balance 0

F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $110.80Direct0 Reported balance After 2023-11-08 transaction · row 12 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 12 · 2023-11-08 · Disposition to issuer · Disposed 889 · Balance 0

F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $110.80Direct0 Reported balance After 2023-11-08 transaction · row 13 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 13 · 2023-11-08 · Disposition to issuer · Disposed 12,811 · Balance 0

F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $99.66Direct0 Reported balance After 2023-11-08 transaction · row 14 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 14 · 2023-11-08 · Disposition to issuer · Disposed 17,700 · Balance 0

F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 28, 2026 Filed May 29, 2026 22:25 UTC Equillium, Inc. EQ · Entity 6560 GrantDirector Stock Option (right to buy) · Derivative 70,000 $0.00 Strike: $2.84 $0.00
Disclosure

SEC source: 0001559569-26-000001 · form4-05292026_100506.xml · derivative · entry 1

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2036-05-27

F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on the grant date of May 28, 2026, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

Read SEC document
May 21, 2025 Filed May 23, 2025 17:45 UTC Equillium, Inc. EQ · Entity 6560 GrantDirector Stock Option (right to buy) · Derivative 20,000 $0.00 Strike: $0.39 $0.00
Disclosure

SEC source: 0001415889-25-014398 · form4-05232025_050525.xml · derivative · entry 1

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2035-05-20

F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on the grant date of May 21, 2025, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

Read SEC document
February 14, 2025 Filed Feb 20, 2025 00:39 UTC Equillium, Inc. EQ · Entity 6560 Disposition to issuerDirector Stock Option (right to buy) · Derivative 20,000 Not disclosed Strike: $2.59 Not disclosed
Disclosure

SEC source: 0001415889-25-004759 · form4-02202025_120216.xml · derivative · entry 8

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2032-05-23

F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged.

F5 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on the grant date of May 24, 2022, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

Read SEC document
February 14, 2025 Filed Feb 20, 2025 00:39 UTC Equillium, Inc. EQ · Entity 6560 GrantDirector Stock Option (right to buy) · Derivative 20,000 Not disclosed Strike: $0.79 Not disclosed
Disclosure

SEC source: 0001415889-25-004759 · form4-02202025_120216.xml · derivative · entry 7

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-05-23

F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged.

F5 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on the grant date of May 24, 2022, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

Read SEC document
February 14, 2025 Filed Feb 20, 2025 00:39 UTC Equillium, Inc. EQ · Entity 6560 Disposition to issuerDirector Stock Option (right to buy) · Derivative 20,770 Not disclosed Strike: $6.55 Not disclosed
Disclosure

SEC source: 0001415889-25-004759 · form4-02202025_120216.xml · derivative · entry 6

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,770 shares

Expires 2031-05-25

F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged.

F4 · derivative.exercise_date: These options vest in twelve equal monthly installments commencing on the grant date of May 26, 2021, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

Read SEC document
February 14, 2025 Filed Feb 20, 2025 00:39 UTC Equillium, Inc. EQ · Entity 6560 GrantDirector Stock Option (right to buy) · Derivative 20,770 Not disclosed Strike: $0.79 Not disclosed
Disclosure

SEC source: 0001415889-25-004759 · form4-02202025_120216.xml · derivative · entry 5

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,770

Underlying: Common Stock · 20,770 shares

Expires 2031-05-25

F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged.

F4 · derivative.exercise_date: These options vest in twelve equal monthly installments commencing on the grant date of May 26, 2021, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

Read SEC document
February 14, 2025 Filed Feb 20, 2025 00:39 UTC Equillium, Inc. EQ · Entity 6560 Disposition to issuerDirector Stock Option (right to buy) · Derivative 24,000 Not disclosed Strike: $2.80 Not disclosed
Disclosure

SEC source: 0001415889-25-004759 · form4-02202025_120216.xml · derivative · entry 4

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 24,000 shares

Expires 2030-05-18

F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged.

F3 · derivative.exercise_date: The options vest in twelve equal monthly installments commencing on the grant date of May 19, 2020, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

Read SEC document
February 14, 2025 Filed Feb 20, 2025 00:39 UTC Equillium, Inc. EQ · Entity 6560 GrantDirector Stock Option (right to buy) · Derivative 24,000 Not disclosed Strike: $0.79 Not disclosed
Disclosure

SEC source: 0001415889-25-004759 · form4-02202025_120216.xml · derivative · entry 3

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2030-05-18

F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged.

F3 · derivative.exercise_date: The options vest in twelve equal monthly installments commencing on the grant date of May 19, 2020, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

Read SEC document
February 14, 2025 Filed Feb 20, 2025 00:39 UTC Equillium, Inc. EQ · Entity 6560 Disposition to issuerDirector Stock Option (right to buy) · Derivative 12,000 Not disclosed Strike: $6.01 Not disclosed
Disclosure

SEC source: 0001415889-25-004759 · form4-02202025_120216.xml · derivative · entry 2

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,000 shares

Expires 2029-06-10

F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged.

F1 · derivative.exercise_date: The shares subject to the option vest in twelve equal monthly installments commencing on the grant date of June 11, 2019, provided, however, that the option will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

Read SEC document
February 14, 2025 Filed Feb 20, 2025 00:39 UTC Equillium, Inc. EQ · Entity 6560 GrantDirector Stock Option (right to buy) · Derivative 12,000 Not disclosed Strike: $0.79 Not disclosed
Disclosure

SEC source: 0001415889-25-004759 · form4-02202025_120216.xml · derivative · entry 1

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2029-06-10

F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged.

F1 · derivative.exercise_date: The shares subject to the option vest in twelve equal monthly installments commencing on the grant date of June 11, 2019, provided, however, that the option will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

Read SEC document
May 22, 2024 Filed May 23, 2024 22:02 UTC Equillium, Inc. EQ · Entity 6560 GrantStock Option (right to buy) · Derivative 20,000 $0.00 Strike: $1.43 $0.00
Disclosure

SEC source: 0001415889-24-014370 · form4-05232024_100533.xml · derivative · entry 1

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2034-05-22

F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on the grant date of May 22, 2024, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:40 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 17,700 Not disclosed Strike: $99.66 Not disclosed
Disclosure

SEC source: 0001104659-23-117094 · tm2330435-13_4seq1.xml · derivative · entry 14

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,700 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:40 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 12,811 Not disclosed Strike: $110.80 Not disclosed
Disclosure

SEC source: 0001104659-23-117094 · tm2330435-13_4seq1.xml · derivative · entry 13

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,811 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:40 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 889 Not disclosed Strike: $110.80 Not disclosed
Disclosure

SEC source: 0001104659-23-117094 · tm2330435-13_4seq1.xml · derivative · entry 12

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 889 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:40 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 45,293 Not disclosed Strike: $58.74 Not disclosed
Disclosure

SEC source: 0001104659-23-117094 · tm2330435-13_4seq1.xml · derivative · entry 11

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 45,293 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:40 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 207 Not disclosed Strike: $58.74 Not disclosed
Disclosure

SEC source: 0001104659-23-117094 · tm2330435-13_4seq1.xml · derivative · entry 10

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 207 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:40 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 38,793 Not disclosed Strike: $107.18 Not disclosed
Disclosure

SEC source: 0001104659-23-117094 · tm2330435-13_4seq1.xml · derivative · entry 9

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 38,793 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:40 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 1,207 Not disclosed Strike: $107.18 Not disclosed
Disclosure

SEC source: 0001104659-23-117094 · tm2330435-13_4seq1.xml · derivative · entry 8

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,207 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:40 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 29,865 Not disclosed Strike: $94.29 Not disclosed
Disclosure

SEC source: 0001104659-23-117094 · tm2330435-13_4seq1.xml · derivative · entry 7

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 29,865 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:40 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 635 Not disclosed Strike: $94.29 Not disclosed
Disclosure

SEC source: 0001104659-23-117094 · tm2330435-13_4seq1.xml · derivative · entry 6

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 635 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:40 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 31,506 Not disclosed Strike: $161.16 Not disclosed
Disclosure

SEC source: 0001104659-23-117094 · tm2330435-13_4seq1.xml · derivative · entry 5

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 31,506 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:40 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 1,044 Not disclosed Strike: $161.16 Not disclosed
Disclosure

SEC source: 0001104659-23-117094 · tm2330435-13_4seq1.xml · derivative · entry 4

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,044 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:40 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 5,401 Not disclosed Strike: $266.01 Not disclosed
Disclosure

SEC source: 0001104659-23-117094 · tm2330435-13_4seq1.xml · derivative · entry 3

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,401 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:40 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 332 Not disclosed Strike: $266.01 Not disclosed
Disclosure

SEC source: 0001104659-23-117094 · tm2330435-13_4seq1.xml · derivative · entry 2

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 332 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:40 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 OtherCommon Stock 618,894 $19.00 $11,758,986.00
Disclosure

SEC source: 0001104659-23-117094 · tm2330435-13_4seq1.xml · nonDerivative · entry 1

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

Read SEC document
May 22, 2023 Filed May 23, 2023 22:04 UTC Equillium, Inc. EQ · Entity 6560 GrantStock Option (right to buy) · Derivative 20,000 $0.00 Strike: $0.65 $0.00
Disclosure

SEC source: 0001209191-23-031713 · doc4.xml · derivative · entry 1

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-05-22

F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on the grant date of May 22, 2023, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

Read SEC document
May 24, 2022 Filed May 25, 2022 23:54 UTC Equillium, Inc. EQ · Entity 6560 GrantStock Option (right to buy) · Derivative 20,000 $0.00 Strike: $2.59 $0.00
Disclosure

SEC source: 0001209191-22-031994 · doc4.xml · derivative · entry 1

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-05-24

F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on the grant date of May 24, 2022, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

Read SEC document
November 30, 2021 Filed Dec 2, 2021 16:05 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 3,817 $17.21 $65,690.57
Disclosure

SEC source: 0001104659-21-145908 · tm2134452-1_4seq1.xml · nonDerivative · entry 2

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 618,894

F2 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit and performance stock unit awards previously granted to the reporting person.

Read SEC document
November 30, 2021 Filed Dec 2, 2021 16:05 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantCommon Stock 6,138 $17.21 $105,634.98
Disclosure

SEC source: 0001104659-21-145908 · tm2134452-1_4seq1.xml · nonDerivative · entry 1

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 622,711

F1 · shares: Represents shares of common stock delivered in respect of performance stock unit awards previously granted to the reporting person; such delivery being made pursuant to the Retirement and Consulting Agreement by and between the Issuer and the reporting person, dated December 9, 2020.

Read SEC document
October 29, 2021 Filed Nov 2, 2021 16:01 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 3,817 $16.86 $64,354.62
Disclosure

SEC source: 0001104659-21-132983 · tm2131701-1_4seq1.xml · nonDerivative · entry 2

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 616,573

F2 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit and performance stock unit awards previously granted to the reporting person.

Read SEC document
October 29, 2021 Filed Nov 2, 2021 16:01 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantCommon Stock 6,138 $16.86 $103,486.68
Disclosure

SEC source: 0001104659-21-132983 · tm2131701-1_4seq1.xml · nonDerivative · entry 1

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 620,390

F1 · shares: Represents shares of common stock delivered in respect of performance stock unit awards previously granted to the reporting person; such delivery being made pursuant to the Retirement and Consulting Agreement by and between the Issuer and the reporting person, dated December 9, 2020.

Read SEC document
September 30, 2021 Filed Oct 4, 2021 17:02 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 3,816 $14.85 $56,667.60
Disclosure

SEC source: 0001104659-21-122560 · tm2129223-1_4seq1.xml · nonDerivative · entry 2

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 614,252

F2 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit and performance stock unit awards previously granted to the reporting person.

Read SEC document
September 30, 2021 Filed Oct 4, 2021 17:02 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantCommon Stock 6,136 $14.85 $91,119.60
Disclosure

SEC source: 0001104659-21-122560 · tm2129223-1_4seq1.xml · nonDerivative · entry 1

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 618,068

F1 · shares: Represents shares of common stock delivered in respect of performance stock unit awards previously granted to the reporting person; such delivery being made pursuant to the Retirement and Consulting Agreement by and between the Issuer and the reporting person, dated December 9, 2020.

Read SEC document
August 31, 2021 Filed Sep 1, 2021 19:01 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 3,817 $14.91 $56,911.47
Disclosure

SEC source: 0001104659-21-112144 · tm2126794-1_4seq1.xml · nonDerivative · entry 2

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 611,932

F2 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit and performance stock unit awards previously granted to the reporting person.

Read SEC document
August 31, 2021 Filed Sep 1, 2021 19:01 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantCommon Stock 6,138 $14.91 $91,517.58
Disclosure

SEC source: 0001104659-21-112144 · tm2126794-1_4seq1.xml · nonDerivative · entry 1

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 615,749

F1 · shares: Represents shares of common stock delivered in respect of performance stock unit awards previously granted to the reporting person; such delivery being made pursuant to the Retirement and Consulting Agreement by and between the Issuer and the reporting person, dated December 9, 2020.

Read SEC document
July 30, 2021 Filed Aug 2, 2021 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 3,817 $17.28 $65,957.76
Disclosure

SEC source: 0001104659-21-099031 · tm2123867-1_4seq1.xml · nonDerivative · entry 2

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 609,611

F2 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit and performance stock unit awards previously granted to the reporting person.

Read SEC document
July 30, 2021 Filed Aug 2, 2021 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantCommon Stock 6,138 $17.28 $106,064.64
Disclosure

SEC source: 0001104659-21-099031 · tm2123867-1_4seq1.xml · nonDerivative · entry 1

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 613,428

F1 · shares: Represents shares of common stock delivered in respect of performance stock unit awards previously granted to the reporting person; such delivery being made pursuant to the Retirement and Consulting Agreement by and between the Issuer and the reporting person, dated December 9, 2020.

Read SEC document
June 30, 2021 Filed Jul 1, 2021 19:01 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 3,816 $19.97 $76,205.52
Disclosure

SEC source: 0001104659-21-088399 · tm2121249-1_4seq1.xml · nonDerivative · entry 2

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 607,290

F2 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit and performance stock unit awards previously granted to the reporting person.

Read SEC document
June 30, 2021 Filed Jul 1, 2021 19:01 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantCommon Stock 6,136 $19.97 $122,535.92
Disclosure

SEC source: 0001104659-21-088399 · tm2121249-1_4seq1.xml · nonDerivative · entry 1

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 611,106

F1 · shares: Represents shares of common stock delivered in respect of performance stock unit awards previously granted to the reporting person; such delivery being made pursuant to the Retirement and Consulting Agreement by and between the Issuer and the reporting person, dated December 9, 2020.

Read SEC document
May 28, 2021 Filed Jun 2, 2021 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 3,817 $16.63 $63,476.71
Disclosure

SEC source: 0001104659-21-075896 · tm2118295d1_4.xml · nonDerivative · entry 2

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 604,970

F2 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit and performance stock unit awards previously granted to the reporting person.

F3 · ownership.direct: Includes 100,000 shares previously held in a grantor retained annuity trust.

Read SEC document
May 28, 2021 Filed Jun 2, 2021 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantCommon Stock 6,138 $16.63 $102,074.94
Disclosure

SEC source: 0001104659-21-075896 · tm2118295d1_4.xml · nonDerivative · entry 1

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 608,787

F1 · shares: Represents shares of common stock delivered in respect of performance stock unit awards previously granted to the reporting person; such delivery being made pursuant to the Retirement and Consulting Agreement by and between the Issuer and the reporting person, dated December 9, 2020.

F3 · ownership.direct: Includes 100,000 shares previously held in a grantor retained annuity trust.

Read SEC document
May 26, 2021 Filed May 28, 2021 22:18 UTC Equillium, Inc. EQ · Entity 6560 GrantStock Option (right to buy) · Derivative 20,770 $0.00 Strike: $6.55 $0.00
Disclosure

SEC source: 0001209191-21-036641 · doc4.xml · derivative · entry 1

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,770

Underlying: Common Stock · 20,770 shares

Expires 2031-05-26

F1 · derivative.exercise_date: These options vest in twelve equal monthly installments commencing on the grant date of May 26, 2021, provided that the options will, in any case, be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2018 Equity Incentive Plan (the "Plan")), through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

Read SEC document
April 30, 2021 Filed May 4, 2021 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 3,817 $19.78 $75,500.26
Disclosure

SEC source: 0001104659-21-061181 · tm2115142d1_4.xml · nonDerivative · entry 2

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 502,649

F2 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit and performance stock unit awards previously granted to the reporting person.

Read SEC document
April 30, 2021 Filed May 4, 2021 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantCommon Stock 6,138 $19.78 $121,409.64
Disclosure

SEC source: 0001104659-21-061181 · tm2115142d1_4.xml · nonDerivative · entry 1

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 506,466

F1 · shares: Represents shares of common stock delivered in respect of performance stock unit awards previously granted to the reporting person; such delivery being made pursuant to the Retirement and Consulting Agreement by and between the Issuer and the reporting person, dated December 9, 2020.

Read SEC document
March 31, 2021 Filed Apr 1, 2021 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 3,658 $23.08 $84,426.64
Disclosure

SEC source: 0001104659-21-045751 · tm2111928d1_form4.xml · nonDerivative · entry 2

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,328

F2 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit and performance stock unit awards previously granted to the reporting person.

Read SEC document
March 31, 2021 Filed Apr 1, 2021 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantCommon Stock 6,136 $23.08 $141,618.88
Disclosure

SEC source: 0001104659-21-045751 · tm2111928d1_form4.xml · nonDerivative · entry 1

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 503,986

F1 · shares: Represents shares of common stock delivered in respect of performance stock unit awards previously granted to the reporting person; such delivery being made pursuant to the Retirement and Consulting Agreement by and between the Issuer and the reporting person, dated December 9, 2020.

Read SEC document
February 26, 2021 Filed Mar 2, 2021 19:01 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 2,741 $21.66 $59,370.06
Disclosure

SEC source: 0001104659-21-030902 · tm218450-2_4seq1.xml · nonDerivative · entry 2

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 497,850

F2 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit and performance stock unit awards previously granted to the reporting person.

Read SEC document
February 26, 2021 Filed Mar 2, 2021 19:01 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantCommon Stock 6,138 $21.66 $132,949.08
Disclosure

SEC source: 0001104659-21-030902 · tm218450-2_4seq1.xml · nonDerivative · entry 1

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,591

F1 · shares: Represents shares of common stock delivered in respect of performance stock unit awards previously granted to the reporting person; such delivery being made pursuant to the Retirement and Consulting Agreement by and between the Issuer and the reporting person, dated December 9, 2020.

Read SEC document
January 29, 2021 Filed Feb 2, 2021 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 2,741 $35.24 $96,592.84
Disclosure

SEC source: 0001104659-21-011073 · tm215092-1_4seq1.xml · nonDerivative · entry 2

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 494,453

F2 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit and performance stock unit awards previously granted to the reporting person.

Read SEC document
January 29, 2021 Filed Feb 2, 2021 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantCommon Stock 6,138 $35.24 $216,303.12
Disclosure

SEC source: 0001104659-21-011073 · tm215092-1_4seq1.xml · nonDerivative · entry 1

Pruzanski Mark · CIK 0001559569 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 497,194

F1 · shares: Represents shares of common stock delivered in respect of performance stock unit awards previously granted to the reporting person; such delivery being made pursuant to the Retirement and Consulting Agreement by and between the Issuer and the reporting person, dated December 9, 2020.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.